Pharmacophores for ligand recognition and activation/inactivation of the Cannabinoid receptors

Current Pharmaceutical Design

Volumn 9, Issue 20, 2003, Pages 1607-1633

  Reggio, Patricia H ^a  

^a KENNESAW STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; 4 [6 METHOXY 2 (4 METHOXYPHENYL) 3 BENZOFURANYLCARBONYL]BENZONITRILE; 5 (1,1 DIMETHYLHEPTYL) 2 (3 HYDROXY 7 HYDROXYMETHYLDECAHYDRO 1 NAPHTHYL)PHENOL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CP 272871; DELTA9(11) TETRAHYDROCANNABINOL; DEXANABINOL; FATTY ACID AMIDASE; G PROTEIN COUPLED RECEPTOR; HYDANTOIN; LIGAND; LIPOXYGENASE; METHANANDAMIDE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; NALOXONE; NOLADIN ETHER; O 1184; O 1966A; RECEPTOR SUBTYPE; RHODOPSIN; RIMONABANT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CIS ISOMER; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG CONFORMATION; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG ISOLATION; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HUMAN; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; TRANS ISOMER;

CANNABINOIDS; DRUG DESIGN; INDOLES; LIGANDS; MODELS, MOLECULAR; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0042991377     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612033454577     Document Type: Review

References (208)

1. Mechoulam R, Gaoni Y. Recent advances in the chemistry of hashish. Fortschr Chem Org Naturst 1967; 25: 175-213.
2. Gaoni Y, Mechoulam R. The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. J Am Chem Soc 1971; 93(1): 217-24.
3. Howlett AC. Pharmacology of cannabinoid receptors. Annu Rev Pharmacol Toxicol 1995; 35: 607-34.
4. Compton DR, Johnson MR, Melvin LS, Martin BR. Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J Pharmacol Exp Ther 1992; 260(1): 201-9.
5. Pertwee R. The evidence for the existence of cannabinoid receptors. Gen Pharmacol 1993; 24(4): 811-24.
6. Pertwee RG, Stevenson LA, Griffin G. Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide. Br J Pharmacol 1993; 110(4): 1483-90.
7. Pertwee RG, Stevenson LA, Elrick DB, Mechoulam R, Corbett AD. Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine. Br J Pharmacol 1992; 105(4): 980-4.
8. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346(6284): 561-4.
9. Shire D, Carillon C, Kaghad M, Calandra B, Rinaldi-Carmona M, Le Fur G, et al. An amino-terminal variant of the central cannabinoid receptor resulting from alternatiye splicing. J Biol Chem 1995; 270(8): 3726-31.
10. Gerard CM, Mollereau C, Vassart G, Parmentier M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 1991; 279(Pt 1): 129-34.
11. Abood ME, Ditto KE, Noel MA, Showalter VM, Tao Q. Isolation and expression of a mouse CB1 cannabinoid receptor gene. Comparison of binding properties with those of native CB1 receptors in mouse brain and N18TG2 neuroblastoma cells. Biochem Pharmacol 1997; 53(2): 207-14.
12. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, et al. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin- like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem 1997; 272(35): 22330-9.
13. Pan X, Ikeda SR, Lewis DL. SR 141716A acts as an inverse agonist to increase neuronal voltage-dependent Ca2+ currents by reversal of tonic CB1 cannabinoid receptor activity. Mol Pharmacol 1998; 54(6): 1064-72.
14. Meschler JP, Kraichely DM, Wilken GH, Howlett AC. Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871) for the CB(1) cannabinoid receptor. Biochem Pharmacol 2000; 60(9): 1315-23.
15. Mato S, Pazos A, Valdizan EM. Cannabinoid receptor antagonism and inverse agonism in response to SR141716A on cAMP production in human and rat brain. Eur J Pharmacol 2002; 443(1-3): 43-6.
16. Kearn CS, Greenberg MJ, DiCamelli R, Kurzawa K, Hillard CJ. Relationships between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP/GTP exchange. J Neurochem 1999; 72(6): 2379-87.
17. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365(6441): 61-5.
18. Griffin G, Tao Q, Abood ME. Cloning and pharmacological characterization of the rat CB(2) cannabinoid receptor. J Pharmacol Exp Ther 2000; 292(3): 886-94.
19. Shire D, Calandra B, Rinaldi-Carmona M, Oustric D, Pessegue B, Bonnin-Cabanne O, et al. Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor. Biochim Biophys Acta 1996; 1307(2): 132-6.
20. Bouaboula M, Desnoyer N, Carayon P, Combes T, Casellas P. Gi protein modulation induced by a selective inverse agonist for the peripheral cannabinoid receptor CB2: implication for intracellular signalization cross-regulation. Mol Pharmacol 1999; 55(3): 473-80.
21. Jarai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR, et al. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA 1999; 96(24): 14136-41.
22. Wagner JA, Varga K, Jarai Z, Kunos G. Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension 1999; 33(1 Pt 2): 429-34.
23. Di Marzo V, Breivogel CS, Tao Q, Bridgen DT, Razdan RK, Zimmer AM, et al. Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J Neurochem 2000; 75(6): 2434-44.
24. Breivogel CS, Griffin G, Di Marzo V, Martin BR. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 2001; 60(1): 155-63.
25. Skaper SD, Buriani A, Dal Toso R, Petrelli L, Romanello S, Facci L, et al. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci U S A 1996; 93(9): 3984-9.
26. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995; 232(1): 54-61.
27. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O, et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 1995; 48(3): 443-50.
28. Glass M, Felder CC. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci 1997; 17(14): 5327-33.
29. Maneuf YP, Brotchie JM. Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices. Br J Pharmacol 1997; 120(8): 1397-8.
30. Felder CC, Joyce KE, Briley EM, Glass M, Mackie KP, Fahey KJ, et al. LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J Pharmacol Exp Ther 1998; 284(1): 291-7.
31. Rhee MH, Bayewitch M, Avidor-Reiss T, Levy R, Vogel Z. Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes. J Neurochem 1998; 71(4): 1525-34.
32. Gebremedhin D, Lange AR, Campbell WB, Hillard CJ, Harder DR. Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. Am J Physiol 1999; 276(6 Pt 2): H2085-93.
33. Caulfield MP, Brown DA. Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br J Pharmacol 1992; 106(2): 231-2.
34. Mackie K, Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci U S A 1992; 89(9): 3825-9.
35. Mackie K, Lai Y, Westenbroek R, Mitchell R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci 1995; 15(10): 6552-61.
36. Pan X, Ikeda SR, Lewis DL. Rat brain cannabinoid receptor modulates N-type Ca2+ channels in a neuronal expression system. Mol Pharmacol 1996; 49(4): 707-14.
37. Henry DJ, Chavkin C. Activation of inwardly rectifying potassium channels (GIRK1) by co-expressed rat brain cannabinoid receptors in Xenopus oocytes. Neurosci Lett 1995; 186(2-3): 91-4.
38. Derkinderen P, Toutant M, Burgaya F, Le Bert M, Siciliano JC, de Franciscis V, et al. Regulation of a neuronal form of focal adhesion kinase by anandamide. Science 1996; 273(5282): 1719-22.
39. Bouaboula M, Poinot-Chazel C, Bourrie B, Canat X, Calandra B, Rinaldi-Carmona M, et al. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J 1995; 312(Pt 2): 637-41.
40. Ho BY, Uezono Y, Takada S, Takase I, Izumi F. Coupling of the expressed cannabinoid CB1 and CB2 receptors to phospholipase C and G protein-coupled inwardly rectifying K+ channels. Receptors Channels 1999; 6(5): 363-74.
41. Bouaboula M, Poinot-Chazel C, Marchand J, Canat X, Bourrie B, Rinaldi-Carmona M, et al. Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur J Biochem 1996; 237(3): 704-11.
42. Stefano GB, Salzet M, Magazine HI, Bilfinger TV. Antagonism of LPS and IFN-gamma induction of iNOS in human saphenous vein endothelium by morphine and anandamide by nitric oxide inhibition of adenylate cyclase. J Cardiovasc Pharmacol 1998; 31(6): 813-20.
43. Fimiani C, Mattocks D, Cavani F, Salzet M, Deutsch DG, Pryor S, et al. Morphine and anandamide stimulate intracellular calcium transients in human arterial endothelial cells: coupling to nitric oxide release. Cell Signal 1999; 11(3): 189-93.
44. Mombouli JV, Schaeffer G, Holzmann S, Kostner GM, Graier WF. Anandamide-induced mobilization of cytosolic Ca2+ in endothelial cells. Br J Pharmacol 1999; 126(7): 1593-600.
45. Maccarrone M, Bari M, Lorenzon T, Bisogno T, Di Marzo V, Finazzi-Agro A. Anandamide uptake by human endothelial cells and its regulation by nitric oxide. J Biol Chem 2000; 275(18): 13484-92.
46. Stefano GB, Liu Y, Goligorsky MS. Cannabinoid receptors are coupled to nitric oxide release in invertebrate immuno-cytes, microglia, and human monocytes. J Biol Chem 1996; 271(32): 19238-42.
47. Devane WA, Dysarz FA, 3rd, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988; 34(5): 605-13.
48. Melvin LS, Milne GM, Johnson MR, Wilken GH, Howlett AC. Structure-activity relationships defining the ACD-tricyclic cannabinoids: cannabinoid receptor binding and analgesic activity. Drug Des Discov 1995; 13(2): 155-66.
49. D'Ambra TE, Estep KG, Bell MR, Eissenstat MA, Josef KA, Ward SJ, et al. Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. J Med Chem 1992; 35(1): 124-35.
50. Ward SJ, Baizman E, Bell M, Childers S, D'Ambra T, Eissenstat M, et al. Aminoalkylindoles (AAIs): a new route to the cannabinoid receptor? NIDA Res Monogr 1991; 105: 425-6.
51. Compton DR, Gold LH, Ward SJ, Balster RL, Martin BR. Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther 1992; 263(3): 1118-26.
52. Reggio PH, Panu AM, Miles S. Characterization of a region of steric interference at the cannabinoid receptor using the active analog approach. J Med Chem 1993; 36(12): 1761-71.
53. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258(5090): 1946-9.
54. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50(1): 83-90.
55. Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 1997; 388(6644): 773-8.
56. Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, et al. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A 2001; 98(7): 3662-5.
57. Wilson RI, Nicoll RA. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 2001; 410(6828): 588-92.
58. Herkenham M. Characterization and localization of cannabinoid receptors in brain: an in vitro technique using slide-mounted tissue sections. NIDA Res Monogr 1991; 112: 129-45.
59. Matsuda LA, Bonner TI, Lolait SJ. Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol 1993; 327(4): 535-50.
60. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998; 83(2): 393-411.
61. Di Marzo V, Melck D, Bisogno T, De Petrocellis L. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci 1998; 21(12): 521-8.
62. Piomelli D, Beltramo M, Giuffrida A, Stella N. Endogenous cannabinoid signaling. Neurobiol Dis 1998; 5(6 Pt B): 462-73.
63. Levenes C, Daniel H, Soubrie P, Crepel F. Cannabinoids decrease excitatory synaptic transmission and impair long-term depression in rat cerebellar Purkinje cells. J Physiol 1998; 5 10(Pt 3): 867-79.
64. Egertova M, Giang DK, Cravatt BF, Elphick MR. A new perspective on cannabinoid signalling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. Proc R Soc Lond B Biol Sci 1998; 265(1410): 2081-5.
65. Hoffman AF, Lupica CR. Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus. J Neurosci 2000; 20(7): 2470-9.
66. Kreitzer AC, Regehr WG. Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron 2001; 29(3): 717-27.
67. Ohno-Shosaku T, Maejima T, Kano M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 2001; 29(3): 729-38.
68. Takahashi KA, Linden DJ. Cannabinoid receptor modulation of synapses received by cerebellar Purkinje cells. J Neurophysiol 2000; 83(3): 1167-80.
69. Bisogno T, Berrendero F, Ambrosino G, Cebeira M, Ramos JA, Fernandez-Ruiz JJ, et al. Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem Biophys Res Commun 1999; 256(2): 377-80.
70. Maejima T, Hashimoto K, Yoshida T, Aiba A, Kano M. Presynaptic inhibition caused by retrograde signal from metabotropic glutamate to cannabinoid receptors. Neuron 2001; 31(3): 463-75.
71. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994; 372(6507): 686-91.
72. Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 1997; 277(5329): 1094-7.
73. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A 2001; 98(16): 9371-6.
74. Glaser ST, Abumrad NA, Fatade F, Kaczocha M, Studholme KM, Deutsch DG. Evidence against the presence of an anandamide transporter. Proc Natl Acad Sci USA 2003; 100(7): 4269-74.
75. Bracey MH, Hanson MA, Masuda KR, Stevens RC, Cravatt BF. Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling. Science 2002; 298(5599): 1793-6.
76. Reggio PH. Endocannabinoid structure-activity relationships for interaction at the cannabinoid receptors. Prostaglandins Leukot Essent Fatty Acids 2002; 66(2-3): 143-60.
77. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002; 418(6897): 530-4.
78. Sanchez C, de Ceballos ML, del Pulgar TG, Rueda D, Corbacho C, Velasco G, et al. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res 2001; 61(15): 5784-9.
79. Pertwee RG. Cannabinoids and the gastrointestinal tract. Gut 2001; 48(6): 859-67.
80. Pertwee RG. Cannabinoid receptors and pain. Prog Neurobiol 2001; 63(5): 569-611.
81. Pertwee RG. Cannabinoids and multiple sclerosis. Pharmacol Ther 2002; 95(2): 165-74.
82. Pertwee RG. Medical uses of cannabinoids: the way forward. Addiction 1999; 94(3): 317-20.
83. Pertwee RG. Neuropharmacology and therapeutic potential of cannabinoids. Addict. Biol. 2000; 5: 37-46.
84. Piomelli D, Giuffrida A, Calignano A, Rodriguez de Fonseca F. The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci 2000; 21(6): 218-24.
85. Abood ME, Martin BR. Neurobiology of marijuana abuse. Trends Pharmacol Sci 1992; 13(5): 201-6.
86. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994; 350(2-3): 240-4.
87. Hosohata K, Quock RM, Hosohata Y, Burkey TH, Makriyannis A, Consroe P, et al. AM630 is a competitive cannabinoid receptor antagonist in the guinea pig brain. Life Sci 1997; 61(9): PL115-8.
88. Hosohata Y, Quock RM, Hosohata K, Makriyannis A, Consroe P, Roeske WR, et al. AM630 antagonism of cannabinoid-stimulated [35S]GTP gamma S binding in the mouse brain. Eur J Pharmacol 1997; 321(1): R1-3.
89. Pertwee R, Griffin G, Fernando S, Li X, Hill A, Makriyannis A. AM630, a competitive cannabinoid receptor antagonist. Life Sci 1995; 56(23-24): 1949-55.
90. Ross RA, Brockie HC, Fernando SR, Saha B, Razdan RK, Pertwee RG. Comparison of cannabinoid binding sites in guinea-pig forebrain and small intestine. Br J Pharmacol 1998; 125(6): 1345-51.
91. Stoit AR, Lange JHM, den Hartog AP, Ronken E, Tipker K, van Stuivenberg HH, et al. Design, synthesis and biological activity of rigid cannabinoid CB1 receptor antagonists. Chem. Pharm. Bull. 2002; 50(8): 1109-13.
92. Sim-Selley LJ, Brunk LK, Selley DE. Inhibitory effects of SR141716A on G-protein activation in rat brain. Eur J Pharmacol 2001; 414(2-3): 135-43.
93. Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 1998; 284(2): 644-50.
94. Iwamura H, Suzuki H, Ueda Y, Kaya T, Inaba T. In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. J Pharmacol Exp Ther 2001; 296(2): 420-5.
95. Terranova JP, Storme JJ, Lafon N, Perio A, Rinaldi-Carmona M, Le Fur G, et al. Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology (Berl) 1996; 126(2): 165-72.
96. Nakanishi K, Zhang H, Lerro KA, Takekuma S, Yamamoto T, Lien TH, et al. Photoaffinity Labeling of Rhodopsin and Bacteriorhodopsin. Biophys. Chem. 1995; 56: 13-22.
97. Razdan RK. Structure-activity relationships in cannabinoids. Pharmacol Rev 1986; 38(2): 75-149.
98. Makriyannis A, Rapaka RS. The molecular basis of cannabinoid activity. Life Sci 1990; 47(24): 2173-84.
99. Xie XQ, Pavlopoulos S, DiMeglio CM, Makriyannis A. Conformational studies on a diastereoisomeric pair of tricyclic nonclassical cannabinoids by NMR spectroscopy and computer molecular modeling. J Med Chem 1998: 41(2): 167-74.
100. Xie XQ, Melvin LS, Makriyannis A. The conformational properties of the highly selective cannabinoid receptor ligand CP-55,940. J Biol Chem 1996; 271(18): 10640-7.
101. Xie XQ, Yang DP, Melvin LS, Makriyannis A. Conformational analysis of the prototype nonclassical cannabinoid CP-47,497, using 2D NMR and computer molecular modeling. J Med Chem 1994; 37(10): 1418-26.
102. Lagu SG, Varona A, Chambers JD, Reggio PH. Construction of a steric map of the binding pocket for cannabinoids at the cannabinoid receptor. Drug Des Discov 1995; 12(3): 179-92.
103. Melvin LS, Johnson MR. Structure-activity relationships of tricyclic and nonclassical bicyclic cannabinoids. NIDA Res Monogr 1987; 79: 31-47.
104. Howlett AC, Johnson MR, Melvin LS, Milne GM. Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model. Mol Pharmacol 1988; 33(3): 297-302.
105. Song ZH, Bonner TI. A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. Mol Pharmacol 1996; 49(5): 891-6.
106. Huffman JW, Yu S, Showalter V, Abood ME, Wiley JL, Compton DR, et al. Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. J Med Chem 1996; 39(20): 3875-7.
107. Drake DJ, Jensen RS, Busch-Petersen J, Kawakami JK, Concepcion Fernandez-Garcia M, Fan P, et al. Classical/nonclassical hybrid cannabinoids: southern aliphatic chain-functionalized C-6beta methyl, ethyl, and propyl analogues. J Med Chem 1998; 41(19): 3596-608.
108. Tius MA, Makriyannis A, Zou XL, Abadji V. Tetrahedron 1994; 50: 2671.
109. Thomas BF, Compton DR, Martin BR, Semus SF. Modeling the cannabinoid receptor: a three-dimensional quantitative structure-activity analysis. Mol Pharmacol 1991; 40(5): 656-65.
110. Schmetzer S, Greenidge P, Kovar KA, Schulze-Alexandru M, Folkers G. Structure-activity relationships of cannabinoids: a joint CoMFA and pseudoreceptor modelling study. J Comput Aided Mol Des 1997; 11(3): 278-92.
111. Papahatjis DP, Nikas SP, Andreou T, Makriyannis A. Novel 1′,1′-chain substituted Delta(8)-tetrahydrocannabinols. Bioorg Med Chem Lett 2002; 12(24): 3583-6.
112. Khanolkar AD, Lu D, Fan P, Tian X, Makriyannis A. Novel conformationally restricted tetracyclic analogs of delta-8-tetrahydrocannabinol. Bioorg Med Chem Lett 1999; 9(15): 2119-24.
113. Papahatjis DP, Kourouli T, Abadji V, Goutopoulos A, Makriyannis A. Pharmacophoric requirements for cannabinoid side chains: multiple bond and C1′-substituted delta 8-tetrahydrocannabinols. J Med Chem 1998; 41(7): 1195-200.
114. Busch-Petersen J, Hill WA, Fan P, Khanolkar A, Xie XQ, Tius MA, et al. Unsaturated side chain beta-11-hydroxyhexahydrocannabinol analogs. J Med Chem 1996; 39(19): 3790-6.
115. Ryan W, Singer M, Razdan RK, Compton DR, Martin BR. A novel class of potent tetrahydrocannabinols (THCS): 2′-yne-delta 8- and delta 9-THCS. Life Sci 1995; 56(23-24): 2013-20.
116. Martin BR, Jefferson R, Winckler R, Wiley JL, Huffman JW, Crocker PJ, et al. Manipulation of the tetrahydrocannabinol side chain delineates agonists, partial agonists, and antagonists. J Pharmacol Exp Ther 1999; 290(3): 1065-79.
117. Singer M, Ryan WJ, Saha B, Martin BR, Razdan RK. Potent cyano and carboxamido side-chain analogues of 1′, 1′-dimethyl-delta-8-tetrahydrocannabinol. J Med Chem 1998; 41(22): 4400-7.
118. Ross RA, Gibson TM, Stevenson LA, Saha B, Crocker P, Razdan RK, et al. Structural determinants of the partial agonist-inverse agonist properties of 6′-azidohex-2′-yne-delta-8-tetrahydrocannabinol at cannabinoid receptors. Br J Pharmacol 1999; 128(3): 735-43.
119. Griffin G, Wray EJ, Rorrer WK, Crocker PJ, Ryan WJ, Saha B, et al. An investigation into the structural determinants of cannabinoid receptor ligand efficacy. Br J Pharmacol 1999; 126(7): 1575-84.
120. Keimowitz AR, Martin BR, Razdan RK, Crocker PJ, Mascarella SW, Thomas BF. QSAR analysis of Delta(8)-THC analogues: relationship of side-chain conformation to cannabinoid receptor affinity and pharmacological potency. J Med Chem 2000; 43(1): 59-70.
121. Gallant M, Dufresne C, Gareau Y, Guay D, Leblanc Y, Prasit P, et al. New Class of Potent Ligands for the Human Peripheral Cannabinoid Receptor. Bioorg. Med. Chem. Lett. 1996; 6: 2263-8.
122. Reggio PH, Wang T, Brown AE, Fleming DN, Seltzman HH, Griffin G et al. Importance of the C-1 substituent in classical cannabinoids to CB2 receptor selectivity: synthesis and characterization of a series of 0,2-propano-delta 8-tetrahydrocannabinol analogs. J Med Chem 1997; 40(20): 3312-8.
123. Melvin LS, Milne GM, Johnson MR, Subramaniam B, Wilken GH, Howlett AC. Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs. Mol Pharmacol 1993; 44(5): 1008-15.
124. Wiley JL, Beletskaya ID, Ng EW, Dai Z, Crocker PJ, Mahadevan A, et al. Resorcinol derivatives: a novel template for the development of cannabinoid CB(1)/CB(2) and CB(2)-selective agonists. J Pharmacol Exp Ther 2002; 301(2): 679-89.
125. Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, et al. HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 1999; 96(25): 14228-33.
126. Huffman JW, Yu S, Liddle J, Wiley JL, Abood M, Martin BR, et al: 1998 Symposium on the Cannabinoids; International Cannabinoid Research Society; Burlington, VT. 1998: 10 [ISBN: 09658053-2-8].
127. Huffman JW, Liddle J, Yu S, Aung MM, Abood ME, Wiley JL, et al. 3-(1′, 1′-Dimethylbutyl)-1-deoxy-delta-8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem 1999; 7(12): 2905-14.
128. Huffman JW, Bushell SM, Miller JR, Wiley JL, Martin BR. 1-Methoxy-, 1-deoxy-11-hydroxy- and 11-Hydroxy-1-methoxy-Delta(8)-tetrahydrocannabinols: new selective ligands for the CB(2) receptor. Bioorg Med Chem 2002; 10(12): 4119-29.
129. Rabinovich AL, Ripatti PO. On the Conformational, Physical Properties and Function of Polyunsaturated AcylChains. Biochim. Biophys. Acta. 1991; 1085: 53-6.
130. Rich MR. Conformational Analysis of Arachidonic and Related Fatty Acids Using Molecular Dynamics Simulations. Biochim. Biophys. Acta. 1993; 1178: 87-96.
131. Barnett-Norris J, Guarnieri F, Hurst DP, Reggio PH. Exploration of biologically relevant conformations of anandamide, 2-arachidonylglycerol, and their analogues using conformational memories. J Med Chem 1998; 41(24): 4861-72.
132. Ernst J, Sheldrick WS, Fuhrop JH. The Structures of the Essential Unsaturated Fatty Acids. Crystal Structure of Linoleic Acid and Evidence for the Crystal Structures of alpha-Linoleic and Arachidonic Acid. Z. Naturforsch 1979; 34b: 706-11.
133. Corey EJ, Niwa H, Falck JR. Selective Epoxidation of Eicosa-cis-5, 8, 11, 14-tetraenoic (Arachidonic) Acid and Eicosa-cis-8, 11,14-trienoic Acid. J. Amer. Chem. Soc. 1979; 101: 1586-7.
134. LaLonde JM, Levenson MA, Roe JJ, Bernlohr DA, Banaszak LJ. Adipocyte lipid-binding protein complexed with arachidonic acid. Titration calorimetry and X-ray crystallographic studies. J Biol Chem 1994; 269(41): 25339-47.
135. Malkowski MG, Ginell SL, Smith WL, Garavito RM. The productive conformation of arachidonic acid bound to prostaglandin synthase. Science 2000; 289(5486): 1933-7.
136. Reggio PH, Traore H. Conformational requirements for endocannabinoid interaction with the cannabinoid receptors, the anandamide transporter and fatty acid amidohydrolase. Chem Phys Lipids 2000; 108(1-2): 15-35.
137. Barnett-Norris J, Hurst DP, Lynch DL, Guarnieri F, Makriyannis A, Reggio PH. Conformational memories and the endocannabinoid binding site at the cannabinoid CB1 receptor. J Med Chem 2002; 45(17): 3649-59.
138. Sheskin T, Hanus L, Slager J, Vogel Z, Mechoulam R. Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J Med Chem 1997; 40(5): 659-67.
139. Seltzman HH, Fleming DN, Thomas BF, Gilliam AF, McCallion DS, Pertwee RG, et al. Synthesis and pharmacological comparison of dimethylheptyl and pentyl analogs of anandamide. J Med Chem 1997; 40(22): 3626-34.
140. Ryan WJ, Banner WK, Wiley JL, Martin BR, Razdan RK. Potent anandamide analogs: the effect of changing the length and branching of the end pentyl chain. J Med Chem 1997; 40(22): 3617-25.
141. Pinto JC, Potie F, Rice KC, Boring D, Johnson MR, Evans DM, et al. Cannabinoid receptor binding and agonist activity of amides and esters of arachidonic acid. Mol Pharmacol 1994; 46(3): 516-22.
142. Berglund BA, Boring DL, Howlett AC. Investigation of structural analogs of prostaglandin amides for binding to and activation of CB1 and CB2 cannabinoid receptors in rat brain and human tonsils. Adv Exp Med Biol 1999; 469: 527-33.
143. Berglund BA, Fleming PR, Rice KC, Shim JY, Welsh WJ, Howlett AC. Development of a novel class of monocyclic and bicyclic alkyl amides that exhibit CB1 and CB2 cannabinoid receptor affinity and receptor activation. Drug Des Discov 2000; 16(4): 281-94.
144. Berglund BA, Boring DL, Wilken GH, Makriyannis A, Howlett AC, Lin S. Structural requirements for arachidonylethanolamide interaction with CB1 and CB2 cannabinoid receptors: pharmacology of the carbonyl and ethanolamide groups. Prostaglandins Leukot Essent Fatty Acids 1998; 59(2): 111-8.
145. Lin S, Khanolkar AD, Fan P, Goutopoulos A, Qin C, Papahadjis D, et al. Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. J Med Chem 1998; 41(27): 5353-61.
146. Ng EW, Aung MM, Abood ME, Martin BR, Razdan RK. Unique analogues of anandamide: arachidonyl ethers and carbamates and norarachidonyl carbamates and ureas. J Med Chem 1999; 42(11): 1975-81.
147. Abadji V, Lin S, Taha G, Griffin G, Stevenson LA, Pertwee RG, et al. (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem 1994; 37(12): 1889-93.
148. Adams IB, Ryan W, Singer M, Razdan RK, Compton DR, Martin BR. Pharmacological and behavioral evaluation of alkylated anandamide analogs. Life Sci 1995; 56(23-24): 2041-8.
149. Goutopoulos A, Fan P, Khanolkar AD, Xie XQ, Lin S, Makriyannis A. Stereochemical selectivity of methanandamides for the CB1 and CB2 cannabinoid receptors and their metabolic stability. Bioorg Med Chem 2001; 9(7): 1673-84.
150. Hillard CJ, Manna S, Greenberg MJ, DiCamelli R, Ross RA, Stevenson LA, et al. Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CBI). J Pharmacol Exp Ther 1999; 289(3): 1427-33.
151. Adams IB, Ryan W, Singer M, Thomas BF, Compton DR, Razdan RK, et al. Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs. J Pharmacol Exp Ther 1995; 273 (3): 1172-81.
152. Lang W, Qin C, Lin S, Khanolkar AD, Goutopoulos A, Fan P, et al. Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase. J Med Chem 1999; 42(5): 896-902.
153. Khanolkar AD, Abadji V, Lin S, Hill WA, Taha G, Abouzid K, et al. Head group analogs of arachidonyl-ethanolamide, the endogenous cannabinoid ligand. J Med Chem 1996; 39(22): 4515-9.
154. Edgemond WS, Hillard CJ, Falck JR, Kearn CS, Campbell WB. Human platelets and polymorphonuclear leukocytes synthesize oxygenated derivatives of arachidonylethanolamide (anandamide): their affinities for cannabinoid receptors and pathways of inactivation. Mol Pharmacol 1998; 54(1): 180-8.
155. Edgemond WS, Campbell WB, Hillard CJ. The binding of novel phenolic derivatives of anandamide to brain cannabinoid receptors. Prostaglandins Leukot Essent Fatty Acids 1995; 52(2-3): 83-6.
156. Thomas BF, Adams IB, Mascarella SW, Martin BR, Razdan RK. Structure-activity analysis of anandamide analogs: relationship to a cannabinoid pharmacophore. J Med Chem 1996; 39(2): 471-9.
157. Tong W, Collantes ER, Welsh WJ, Berglund BA, Howlett AC. Derivation of a pharmacophore model for anandamide using constrained conformational searching and comparative molecular field analysis. J Med Chem 1998; 41(22): 4207-15.
158. Stegeman R, Pawlitz J, Stevens A, Gierse J, Stallings W, Kurumbail R. American Crystallographic Association, Abstract. 1998.
159. van der Stelt M, van Kuik JA, Bari M, van Zadelhoff G, Leeflang BR, Veldink GA et al. Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase. J Med Chem 2002; 45(17): 3709-20.
160. Guarnieri F, Weinstein H. Conformational Memories and the Exploration of Biologically Relevant Peptide Conformations: An Illustration for the Gonadotropin-Releasing Hormone. J. Amer. Chem. Soc. 1996; 118: 5580-9.
161. Bonechi C, Brizzi A, Brizzi V, Francoli M, Donati A, Rossi C. Conformational analysis of N-arachidonylethanolamide (anandamide) using nuclear magnetic Rresonance and theoretical calculations. Magn. Reson. Chem. 2001; 39: 432-7.
162. Reggio P, Hurst D, Buehner K, Norris JB, McAllister SD, Abood ME. The TMH 3-4-5-6 Aromatic Rich Region of CB1: Importance of aromatic stacking interactions for the binding of SR141716A and WIN55,212-2 and C-H⋯pi interactions for the binding of anandamide. 2002 Symposium on the Cannabinoids. Pacific Grove, CA: International Cannabinoid Research Society, 2002. pp. 6.
163. Barnett-Norris J, Hurst DP, Buehner K, Ballesteros JA, Guarnieri F, Reggio PH. Agonist alkyl tail interaction with cannabinoid CB1 receptor V6.43/I6.46 groove induces a Helix 6 active conformation. Int. J. Quantum Chem. 2002; 88(1): 76-86.
164. Chin C, Lucas-Lenard J, Abadji V, Kendall DA. Ligand Binding and Modulation of Cyclic AMP Levels Depend on the Chemical Nature of Residue 192 of the Human Cannabinoid Receptor 1. J. Neurochem 1998; 70: 366-73.
165. Reggio PH, Basu-Dutt S, Barnett-Norris J, Castro MT, Hurst DP, Seltzman HH, et al. The bioactive conformation of aminoalkylindoles at the cannabinoid CB1 and CB2 receptors: insights gained from (E)- and (Z)-naphthylidene indenes. J Med Chem 1998; 41(26): 5177-87.
166. Kumar V, Alexander MD, Bell MR, Eissenstat MA, Casiano FM, Chippari SM, et al. Morpholinoalkylindenes as Antinociceptive Agents: Novel Cannabinoid Receptor Agonists. Bioorg. Med. Chem. Lett. 1995; 5: 381-6.
167. Eissenstat MA, Bell MR, D'Ambra TE, Alexander EJ, Daum SJ, Ackerman JH, et al. Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics. J Med Chem 1995; 38(16): 3094-105.
168. Shim JY, Collantes ER, Welsh WJ, Subramaniam B, Howlett AC, Eissenstat MA, et al. Three-dimensional quantitative structure-activity relationship study of the cannabimimetic (aminoalkyl)indoles using comparative molecular field analysis. J Med Chem 1998; 41(23): 4521-32.
169. Xie XQ, Han XW, Chen JZ, Eissenstat M, Makriyannis A. High-resolution NMR and computer modeling studies of the cannabimimetic aminoalkylindole prototype WIN-55212-2. J Med Chem 1999; 42(20): 4021-7.
170. Dutta AK, Ryan W, Thomas BF, Singer M, Compton DR, Martin BR, et al. Synthesis, pharmacology, and molecular modeling of novel 4-alkyloxy indole derivatives related to cannabimimetic aminoalkyl indoles (AAIs). Bioorg Med Chem 1997; 5(8): 1591-600.
171. Xie XQ, Eissenstat M, Makriyannis A. Common cannabimimetic pharmacophoric requirements between aminoalkyl indoles and classical cannabinoids. Life Sci 1995; 56(23-24): 1963-70.
172. Huffman JW, Dai D, Martin BR, Compton DR. Design, Synthesis and Pharmacology of Cannabimimetic Indoles. Bioorg. Med. Chem. Lett. 1994; 4: 563-6.
173. Wiley JL, Compton DR, Dai D, Lainton JA, Phillips M, Huffman JW, et al, Structure-activity relationships of indole- and pyrrole-derived cannabinoids. J Pharmacol Exp Ther 1998; 285(3): 995-1004.
174. Reggio PH, Basu-Dutt S, Barnett-Norris J, Castro MT, Hurst DP, Seltzman HH, et al. The Bioactive Conformation of Aminoalkylindoles at the Cannabinoid CB1 and CB2 Receptors: Insights gained from E and Z Naphthylindene Indenes. J. Med. Chem. 1998.
175. Song ZH, Slowey CA, Hurst DP, Reggio PH. The difference between the CB(1) and CB(2) cannabinoid receptors at position 5.46 is crucial for the selectivity of WIN55212-2 for CB(2). Mol Pharmacol 1999; 56(4): 834-40.
176. Shire D, Calandra B, Bouaboula M, Barth F, Rinaldi-Carmona M, Casellas P, et al. Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528. Life Sci 1999; 65(6-7): 627-35.
177. Huffman JW, Mabon R, Wu MJ, Lu J, Hart R, Hurst DP, et al. 3-Indolyl-1-naphthylmethanes: new cannabimimetic indoles provide evidence for aromatic stacking interactions with the CB(1) cannabinoid receptor. Bioorg Med Chem 2003; 11(4): 539-49.
178. Thomas BF, Gilliam AF, Burch DF, Roche MJ, Seltzman HH. Comparative receptor binding analyses of cannabinoid agonists and antagonists. J Pharmacol Exp Ther 1998; 285(1): 285-92.
179. Francisco ME, Seltzman HH, Gilliam AF, Mitchell RA, Rider SL, Pertwee RG, et al. Synthesis and structure-activity relationships of amide and hydrazide analogues of the cannabinoid CB(1) receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methyl-1H-pyrazole-3-carboxamide (SR141716). J Med Chem 2002; 45(13): 2708-19.
180. Lan R, Liu Q, Fan P, Lin S, Fernando SR, McCallion D, et al. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem 1999; 42(4): 769-76.
181. Wiley JL, Jefferson RG, Grier MC, Mahadevan A, Razdan RK, Martin BR. Novel pyrazole cannabinoids: insights into CB(1) receptor recognition and activation. J Pharmacol Exp Ther 2001; 296(3): 1013-22.
182. Shim J-Y, Collantes ER, Welsh WJ, Howlett AC. Unified pharmacophoric model for cannabinoids and aminoalkyl-indoles derived from molecular superimposition of CB1 cannabinoid receptor agonists CP55244 and WIN55212-2. ACS Symp. Ser. 1999; 719 (Rational Drug Design): 165-84.
183. Shim JY, Welsh WJ, Cartier E, Edwards JL, Howlett AC. Molecular interaction of the antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1- (2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide with the CB1 cannabinoid receptor. J Med Chem 2002; 45(7): 1447-59.
184. Hurst DP, Lynch DL, Barnett-Norris J, Hyatt SM, Seltzman HH, Zhong M, et al. N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl -4-methyl-1H-p yrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Mol Pharmacol 2002; 62(6): 1274-87.
185. Kanyonyo M, Govaerts SJ, Hermans E, Poupaert JH, Lambert DM. 3-Alkyl-(5,5′-diphenyl)imidazolidineiones as new cannabinoid receptor ligands. Bioorg Med Chem Lett 1999; 9(15): 2233-6.
186. Ooms F, Wouters J, Oscari O, Happaerts T, Bouchard G, Carrupt PA, et al. Exploration of the pharmacophore of 3-alkyl-5-arylimidazolidinediones as new CB(1) cannabinoid receptor ligands and potential antagonists: synthesis, lipophilicity, affinity, and molecular modeling. J Med Chem 2002; 45(9): 1748-56.
187. Mussinu JM, Ruiu S, Mule AC, Pau A, Carai MA, Loriga G, et al. Tricyclic Pyrazoles. Part 1: Synthesis and Biological Evaluation of Novel 1,4-Dihydroindeno[1,2-c]pyrazol-based Ligands for CB(1)and CB(2)Cannabinoid Receptors. Bioorg Med Chem 2003; 11(2): 251-63.
188. Mignani S, Hittinger O, Archard D, Bouchard H, Bouquerel J, Capet M, et al. Preparation of 1-bis(aryl)methyl-3-(alkylsulfonyl)arylmethyleneazetidines as cannabinoid CB1 receptor antagonists. Chemical Abstracts. France: Aventis Pharma S. A., 2000. pp. 236982s.
189. Leff P. The two-state model of receptor activation. Trends Pharmacol Sci 1995; 16(3): 89-97.
190. Ballesteros JA, Jensen AD, Liapakis G, Rasmussen SG, Shi L, Gether U, et al. Activation of the beta 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J Biol Chem 2001; 276(31): 29171-7.
191. Visiers I, Ebersole BJ, Dracheva S, Ballesteros J, Sealfon SC, Weinstein H. Structural motifs as functional microdomains in G-protein-coupled receptors: Energetic considerations in the mechanism of activation of the serotonin 5-HT2a receptor by disruption of the ionic lock of the arginine cage. Int. J. Quantum Chem. 2002; 88: 65-75.
192. Gether U, Lin S, Ghanouni P, Ballesteros JA, Weinstein H, Kobilka BK. Agonists induce conformational changes in transmembrane domains III and VI of the beta2 adrenoceptor. Embo J 1997; 16(22): 6737-47.
193. Farrens DL, Altenbach C, Yang K, Hubbell WL, Khorana HG. Requirement of Rigid-Body Motion of Transmembrane Helicies for Light-Activation of Rhodopsin. Science 1996; 274: 768-70.
194. Ghanouni P, Steenhuis JJ, Farrens DL, Kobilka BK. Agonist-induced conformational changes in the G-protein-coupling domain of the beta 2 adrenergic receptor. Proc Natl Acad Sci U S A 2001; 98(11): 5997-6002.
195. Jensen AD, Guarnieri F, Rasmussen SG, Asmar F, Ballesteros JA, Gether U. Agonist-induced conformational changes at the cytoplasmic side of transmembrane segment 6 in the beta 2 adrenergic receptor mapped by site-selective fluorescent labeling. J Biol Chem 2001; 276(12): 9279-90.
196. Hulme EC, Lu ZL, Ward SD, Allman K, Curtis CA. The conformational switch in 7-transmembrane receptors: the muscarinic receptor paradigm. Eur J Pharmacol 1999; 375(1-3): 247-60.
197. Lin SW, Sakmar TP. Specific tryptophan UV-absorbance changes are probes of the transition of rhodopsin to its active state. Biochemistry 1996; 35(34): 11149-59.
198. Javitch JA, Fu D, Liapakis G, Chen J. Constitutive activation of the beta2 adrenergic receptor alters the orientation of its sixth membrane-spanning segment. J Biol Chem 1997; 272(30): 18546-9.
199. 2 Receptor: A Mechanistic Hypothesis from Molecular Dynamics Simulations of the Three-Dimensional Model of the Receptor Complexed to Ligands. J. Med. Chem. 1993; 36: 934-8.
200. Colson AO, Perlman JH, Jinsi-Parimoo A, Nussenzveig DR, Osman R, Gershengorn MC. A hydrophobic cluster between transmembrane helices 5 and 6 constrains the thyrotropin-releasing hormone receptor in an inactive conformation. Mol Pharmacol 1998, 54(6): 968-78.
201. Arnis S, Fahmy K, Hofmann KP, Sakmar TP. A conserved carboxylic acid group mediates light-dependent proton uptake and signaling by rhodopsin. J Biol Chem 1994; 269(39): 23879-81.
202. Saam J, Tajkhorshid E, Hayashi S, Schulten K. Molecular dynamics investigation of primary photoinduced events in the activation of rhodopsin. Biophys J 2002; 83(6): 3097-112.
203. Shi L, Liapakis G, Xu R, Guarnieri F, Ballesteros JA, Javitch JA. Beta 2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. J Biol Chem 2002; 277(43): 40989-96.
204. Singh R, Hurst DP, Barnett-Norris J, Lynch DL, Reggio PH, Guarnieri F. Activation of the cannabinoid CB1 receptor may involve a W6.48/F3.36 rotamer toggle switch. J Pept Res 2002; 60(6): 357-70.
205. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, et al. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000; 289(5480): 739-45.
206. Bisogno T, De Petrocellis L, Di Marzo V. Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications. Curr Pharm Des 2002; 8(7): 533-47.
207. Hoffren AM, Murray CM, Hoffmann RD. Structure-based focusing using pharmacophores derived from the active site of l7beta-hydroxysteroid dehydrogenase. Curr Pharm Des 2001; 7(7): 547-66.
208. Karaplis AC. PTHrP: novel roles in skeletal biology. Curr Pharm Des 2001; 7(8): 655-70.